Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer

Share:
FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer

Keytruda, Merck & Co., Inc. (NYSE: MRK)'s flagship cancer immunotherapy, has secured FDA clearance for two more indications, cementing its positioning as the top oncology drug and expanding its lead over Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo.

What Happened

Kenilworth, New-Jersey-based Merck said the FDA has greenlighted Keytruda, an anti-PD-1 therapy, for two indications:

A monotherapy in patients whose tumors express PD-L1 for first-line treatment of patients with metastatic, or with unresectable, recurrent head and neck squamous cell carcinoma, or HNSCC.

Combo therapy along with platinum and fluorouracil, a commonly used chemotherapy, for patients with metastatic or unresectable recurrent HNSCC.

The approval was granted based on positive results from the pivotal Phase 3 KEYNOTE-048 trial, Merck said. 

Why It's Important

Merck's Keytruda is now the first anti-PD-1 therapy for treating head and neck cancer.

"Metastatic or recurrent head and neck cancer has been an area of significant unmet need, so it is encouraging to have immunotherapy regimens available for patients in the first-line setting," Barbara Burtness of the Yale Cancer Center's development therapeutics research program said in a statement. 

Incidentally, Keytruda received approval as a treatment option for recurrent or metastatic HNSCC with disease progression, on or after platinum-containing chemotherapy, in 2016.

What's Next

Merck is awaiting approval of Keytruda as a third-line treatment of advanced small cell lung cancer, with the PDUFA date scheduled for June 17.

The stock was advancing by 0.64 percent to $83.01 in premarket trading Tuesday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Photo courtesy of Merck. 

Posted-In: Biotech News FDA Top Stories Trading Ideas General Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Benzinga's Top Upgrades, Downgrades For June 11, 2019

Cree Cuts Q4 Guidance, Shares Fall